Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Operating Leases (2019 - 2025)

Historic Operating Leases for Puma Biotechnology (PBYI) over the last 7 years, with Q3 2025 value amounting to $7.3 million.

  • Puma Biotechnology's Operating Leases fell 1156.12% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 1156.12%. This contributed to the annual value of $1.5 million for FY2024, which is 7876.03% down from last year.
  • As of Q3 2025, Puma Biotechnology's Operating Leases stood at $7.3 million, which was down 1156.12% from $4.4 million recorded in Q2 2025.
  • Puma Biotechnology's Operating Leases' 5-year high stood at $20.4 million during Q3 2021, with a 5-year trough of $1.5 million in Q4 2024.
  • Its 5-year average for Operating Leases is $12.3 million, with a median of $12.9 million in 2023.
  • As far as peak fluctuations go, Puma Biotechnology's Operating Leases changed by 0.0% in 2021, and later tumbled by 7876.03% in 2024.
  • Over the past 5 years, Puma Biotechnology's Operating Leases (Quarter) stood at $16.0 million in 2021, then fell by 25.92% to $11.8 million in 2022, then tumbled by 40.56% to $7.0 million in 2023, then crashed by 78.76% to $1.5 million in 2024, then soared by 391.03% to $7.3 million in 2025.
  • Its Operating Leases stands at $7.3 million for Q3 2025, versus $4.4 million for Q2 2025 and $5.7 million for Q1 2025.